In a report released today, Soumit Roy from JonesTrading maintained a Hold rating on Cellectis SA (CLLS – Research Report). The company’s shares closed today at $1.85.
According to TipRanks, Roy is an analyst with an average return of -5.2% and a 25.79% success rate. Roy covers the Healthcare sector, focusing on stocks such as Anavex Life Sciences, Oncolytics Biotech, and Cassava Sciences.
Cellectis SA has an analyst consensus of Strong Buy, with a price target consensus of $7.67.
See today’s best-performing stocks on TipRanks >>
CLLS market cap is currently $107.5M and has a P/E ratio of -0.84.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
Read More on CLLS:
- Cellectis reports Q2 adjusted EPS ($1.00), consensus (40c)
- Cellectis Provides Full Report for Second Quarter 2023 Financial Results
- Cellectis reports Q2 EPS (19c), consensus (45c)
- Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
- Monthly information on share capital and company voting rights
